Psychiatrie5 articles

Impact 3

Cost-effectiveness analysis of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the US.

Publié: 2026-12-01

Journal of medical economics

MediLens Indexé: 2026-05-11

This study evaluates the cost-effectiveness of xanomeline and trospium chloride (KarXT) as a first line treatment for schizophrenia. Using a decision tree-Markov hybrid model, the analysis found that KarXT is more costly but also more effective than common generic antipsychotics, yielding favorab...

Lire sur PubMed

Impact 2

Analyzing the direct medical cost of Schizophrenia in Hospital Pulau Pinang, Malaysia.

Publié: 2026-05-11

Expert review of pharmacoeconomics & outcomes research

MediLens Indexé: 2026-05-12

This study evaluates the direct medical costs associated with schizophrenia (SCZ) at Hospital Pulau Pinang in Malaysia. A retrospective analysis of 120 adult patients revealed that the mean annual inpatient cost per patient was MYR 8,483.4, with hospitalization accounting for 62% of this cost. Ou...

Lire sur PubMed

Impact 2

[Disordered eating behaviors and eating disorders among athletes].

Publié: 2026-05-10

Orvosi hetilap

MediLens Indexé: 2026-05-12

This literature review examines the forms and consequences of disordered eating behaviors and eating disorders in athletic populations, highlighting their multifactorial origins. It discusses the significance of the female athlete triad and confirms the involvement of male athletes, particularly ...

Lire sur PubMed

Impact 2

Motivational deficits and anhedonia in schizophrenia: insights from behavioral activation and behavioral inhibition systems.

Publié: 2026-05-10

Annals of general psychiatry

MediLens Indexé: 2026-05-12

This study investigates the relationship between Behavioral Inhibition System (BIS) and Behavioral Activation System (BAS) activity, depressive symptoms, and anhedonia in schizophrenia. Involving 61 patients and 62 healthy controls, the findings indicate that reduced BAS activity in schizophrenia...

Lire sur PubMed

Impact 2

Anxiety, Bipolar, Depressive, and Schizophrenia Diagnoses Among Patients Receiving Addiction Treatment in the United States, 2006-2022: A Descriptive Study.

Publié: 2026-05-10

Substance use & addiction journal

MediLens Indexé: 2026-05-11

This study analyzed mental health diagnoses among patients in addiction treatment from 2006 to 2022, using Joinpoint regression on Treatment Episode Data Set - Admissions. The total sample included 224,051 patients, with 13% having anxiety disorders, 30.3% bipolar disorders, 43.4% depressive diso...

Lire sur PubMed

Tendances de la Recherche Médicale

Psychiatrie5 articles

Cost-effectiveness analysis of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the US.

Analyzing the direct medical cost of Schizophrenia in Hospital Pulau Pinang, Malaysia.

[Disordered eating behaviors and eating disorders among athletes].

Motivational deficits and anhedonia in schizophrenia: insights from behavioral activation and behavioral inhibition systems.

Anxiety, Bipolar, Depressive, and Schizophrenia Diagnoses Among Patients Receiving Addiction Treatment in the United States, 2006-2022: A Descriptive Study.

Recevez des résumés quotidiens personnalisés